Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Artificial pancreas Stories

2012-06-01 02:24:25

-- Partnership Announced Between Leaders of Artificial Pancreas Research and Development to Develop Novel Redundant Sensor System to Help Improve Glucose Control for People with Diabetes -- NEW YORK, June 1, 2012 /PRNewswire-USNewswire/ -- JDRF in collaboration with the Helmsley Charitable Trust (HCT) announced today a partnership with Medtronic, Inc. (NYSE:MDT), a leader in artificial pancreas research and development. The JDRF-HCT Sensor Initiative aims to advance continuous glucose...

2012-05-03 02:31:16

THE WOODLANDS, Texas, May 3, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that an independent, non-profit organization will provide funding to support the Phase 2 development of LX4211 in type 1 diabetes. LX4211, a dual inhibitor of sodium glucose transporter 1 and 2 (SGLT1 and SGLT2), was designed to improve control of blood glucose through mechanisms that do not require the pancreas to produce insulin. In type 1 diabetes, also called...

2012-05-01 20:52:54

A transcription factor activated by too much sugar in the blood is a driver of an implacable cycle of too little insulin resulting in too much sugar in the blood that, in turn, causes failure of beta cells to make enough insulin which results in even higher blood sugar and type 2 diabetes, said researchers from Baylor College of Medicine in an online report in the journal Diabetologia. That transcription factor — carbohydrate response element binding protein or ChREBP — offers...

2012-04-24 02:29:37

--Novel Transmitter Will Simplify Artificial Pancreas Research by Eliminating a Separate CGM component-- NEW YORK, April 24, 2012 /PRNewswire-USNewswire/ -- JDRF, the leading global organization focused on type 1 diabetes (T1D) research, announced today that it has partnered with Dexcom, Inc. (Nasdaq: DXCM), a San Diego, CA-based medical device company focused on developing and marketing continuous glucose monitoring (CGM) systems. The goal of the partnership is to accelerate the...

2012-04-09 09:28:25

Salk researchers find molecular switch that controls liver glucose production and may represent a new avenue for treating insulin-resistant type II diabetes In their extraordinary quest to decode human metabolism, researchers at the Salk Institute for Biological Studies have discovered a pair of molecules that regulates the liver's production of glucose---- the simple sugar that is the source of energy in human cells and the central player in diabetes. In a paper published April 8 in...

2012-03-12 10:00:48

Study suggests a new approach could give patients the ability to make their own insulin-producing cells without a stem cell transplant A study by Columbia researchers suggests that cells in the patient's intestine could be coaxed into making insulin, circumventing the need for a stem cell transplant. Until now, stem cell transplants have been seen by many researchers as the ideal way to replace cells lost in type I diabetes and to free patients from insulin injections. The...

2012-02-03 11:44:54

New study finds exercise in low oxygen environment may result in improved insulin sensitivity Intermittent exercise with and without low oxygen concentrations (or hypoxia) can improve insulin sensitivity in type 2 diabetics, however exercise while under hypoxic conditions provides greater improvements in glycemic control than intermittent exercise alone, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism...

2012-01-20 19:50:00

Sucanon is a breakthrough herbal-based treatment of type 2 diabetes, which unlike traditionally used medication is not associated with side effects or harmful metabolic changes in the body. (PRWEB) January 20, 2012 Sucanon is a breakthrough herbal-based treatment of type 2 diabetes, which unlike traditionally used medication is not associated with side effects or harmful metabolic changes in the body. Although researchers were enthusiastic about Sucanon's ability to effectively address...

2012-01-16 07:30:00

LAGUNA HILLS, Calif., Jan. 16, 2012 /PRNewswire/ -- LoneStar Heart Inc., based here, today announced that it has acquired a worldwide exclusive license from the University of Texas Southwestern Medical Center (UT Southwestern) to commercialize a new class of patented small molecules known as Isoxazoles that markedly increase insulin production in human pancreas cells no longer able to produce insulin. Activating the entire biochemical pathway involved in insulin production,...

2012-01-13 06:51:32

(Ivanhoe Newswire)- Type 1 diabetes is caused by the body's own immune system attacking its pancreatic islet beta cells and requires daily injections of insulin to regulate the patient's blood glucose levels. A new method found in the BioMed Central's open access journal BMC Medicine uses stem cells from cord blood to reeducate the T cells in a diabetic's blood to restart the pancreatic function and reduce the need for insulin. In Stem Cell Educator therapy, lymphocytes were separated from...